drugset / Trial / NCT00532272
Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Primary objective is to evaluate the response rates and clinical benefits of letrozole + goserelin in premenopausal patients versus letrozole alone in postmenopausal patients with metastatic breast cancer as first line hormonal therapy
Timeline
- Start
- 2005-10
- Primary completion
- 2008-04
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Goserelin | Other / unclassified | 3.6 mg | Subcutaneous |
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |